Amgen's Dividend Attractiveness and Strong Leadership Amid Industry Uncertainty

Amgen has been added to the Citywire Global Elite Companies index and highlighted by a dividends screen. Despite uncertainty surrounding drug pricing and tariffs, the pharmaceutical industry is crucial for societal health as populations age. Amgen's dividends and diversity have attracted top managers.

Amgen has recently been added to the Citywire Global Elite Companies index and highlighted by a dividends screen, attracting top managers with its strong dividend performance and diverse portfolio. Despite uncertainty surrounding drug pricing and tariffs, the pharmaceutical industry remains crucial for societal health as populations age.

Amgen's recent regulatory milestones highlight its commitment to innovation and patient care. In December 2024, the company announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk B-cell acute lymphoblastic leukemia (B-ALL) [1]. This breakthrough study, conducted by the Children’s Oncology Group, found that patients receiving the combination therapy achieved a three-year DFS rate of 96%, compared to 87.9% for those treated with chemotherapy alone. The U.S. Food and Drug Administration (FDA) approved BLINCYTO® for treating adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during the consolidation phase of treatment in June 2024 [1].

Amgen's IMDELLTRA™ (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, has shown promising results in small cell lung cancer. The drug was presented at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, showcasing its potential as a targeted immunotherapy option [1]. Amgen also announced the approval of LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for adult patients with KRAS G12C-mutated metastatic colorectal cancer in January 2025 [1].

Amgen's dividends and diversity have attracted top managers. Despite the uncertainty surrounding drug pricing and tariffs, the pharmaceutical industry remains crucial for societal health as populations age. Amgen's strong dividend performance and diverse portfolio have positioned it as a leader in the industry.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/AMGN/fda-events/